Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-24T17:21:59.887Z Has data issue: false hasContentIssue false
  • English
  • Français

Elevated sera levels of galectin-3 in stable schizophrenia

Published online by Cambridge University Press:  23 March 2020

M. Borovcanin ,
I. Jovanovic ,
S. Minic Janicijevic ,
N. Gajovic ,
N. Arsenijevic  and
M. Lukic L.
M. Borovcanin
Affiliation:
Faculty of Medical Sciences, University of Kragujevac, Department of Psychiatry, Kragujevac, Serbia
I. Jovanovic
Affiliation:
Faculty of Medical Sciences, University of Kragujevac, Center for Molecular Medicine and Stem Cell Research, Kragujevac, Serbia
S. Minic Janicijevic
Affiliation:
Clinical Centre Kragujevac, Psychiatric Clinic, Kragujevac, Serbia
N. Gajovic
Affiliation:
Faculty of Medical Sciences, University of Kragujevac, Center for Molecular Medicine and Stem Cell Research, Kragujevac, Serbia
N. Arsenijevic
Affiliation:
Faculty of Medical Sciences, University of Kragujevac, Center for Molecular Medicine and Stem Cell Research, Kragujevac, Serbia
M. Lukic L.
Affiliation:
Faculty of Medical Sciences, University of Kragujevac, Center for Molecular Medicine and Stem Cell Research, Kragujevac, Serbia

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Galectin-3 (Gal-3) is a unique member of the lectin family involved in cell proliferation, adhesion, apoptosis and immune responses. Deletion of the Gal-3 gene reduces experimental autoimmune encephalomyelitis and variation of gene encoding for Gal-3 already showed to be related with cognitive function. Also, elevated Gal-3 sera levels were measured in patients with Alzheimer's disease.

Aims and objectives We measured the serum concentrations of Gal-3 in patients with schizophrenia in remission and try to determine possible correlation of Gal-3 sera levels with clinical parameters, especially cognitive aspects.

Methods

In this pilot study were included patients with schizophrenia in remission on three months stable depot antipsychotic medication (risperidone and paliperidone) (n = 27) and healthy controls (n = 18). Serum levels of Gal-3 were measured using sensitive enzyme-linked immunosorbent assay (ELISA) kits, specific for humans (R&D Systems, Minneapolis). Cognition was evaluated using the Positive and Negative Syndrome Scale (PANSS) cognitive factors.

Results

Higher mean values of Gal-3 were measured in patients with schizophrenia in remission compared with healthy volunteers (1389.69 vs. 994.23 pg/mL; P = 0.011), but correlation with PANSS cognitive factor was not established (P = 0.748).

Conclusions

These findings suggest that the role of Gal-3 should be explored further, in different stages of disorder and depending on applied therapy, but also considering specific cytokine milieu.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster walk: Schizophrenia and other psychotic disorders–part 1
Information
European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. S187
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.